Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy

Fig. 1

NPM1 transcriptionally promotes PD-L1 expression in different cancer cell lines. A The indicated cells were treated with (right) or without (left) 25 ng/ml IFN-γ for 24 h. B PD-L1 mRNA levels in the indicated cell lines were measured by qPCR and normalized fold change values were shown. Gene expression levels of PD-L1 high expression were set at 1.0. C Western blot analysis of NPM1 in the indicated cell lines. D NPM1 was stably knocked down by sgRNAs in MDA-MB-231, HCT116 and A375 cells. The expression of NPM1 and PD-L1 was evaluated. E, F PD-L1 mRNA levels were measured by qPCR (F), and promoter activity was measured by a dual-luciferase reporter assay (E). Data are presented as the mean ± s.d. of three independent experiments, ***P < 0.001, ****P < 0.0001

Back to article page